Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2807433 | 0.97 | EPHX2 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Water SCHEMBL28211286 | 0.97 | EPHX2 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16039854 | 0.87 | — | — | |
| SCHEMBL1397743 | 0.86 | EPHX2 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11148894 | 0.73 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1072721 | 0.73 | GRIN2D (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL11156721 | 0.71 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2909470 | 0.71 | — | — | |
| SCHEMBL3079393 | 0.69 | EPHX2 (0.58) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3069160 | 0.69 | EPHX2 (1.00) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021116897-A1 | PROCESS FOR THE PREPARATION OF VILDAGLIPTIN | OPTIMUS DRUGS (P) LTD (IN) | 2021-06-17 | — | — | WO | disclosed |
| EP-3110795-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | Hikal Limited (IN) | 2017-01-04 | — | — | EP | disclosed |
| EP-1953145-B1 | HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO (JP) | 2015-11-04 | — | — | EP | disclosed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-8927549-B2 | Adamantyl benzamide derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| EP-1620396-B1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED 2-CYANOPYRROLIDINES | NOVARTIS AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| US-8383622-B2 | Nitrogen-containing heterocyclic derivative having 11β-hydroxysteroid dehydrogenase type I inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8324265-B2 | Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362730-A1 | ADAMANTYL BENZAMIDE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-1021430-A1 | FURAN NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6051571-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6040444-A | Process for preparing furan nitrone compounds | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5942507-A | REAGANTS FOR DETECTION FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999020601-A1 | α-ARYL-N-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998003496-A1 | FURAN NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5707985-A | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators | TANABE SEIYAKU CO. LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-4678797-A | INSECTICIDES, MITICIDES, NEMATOCIDES, FUNGICIDES, FEED UTILIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 1987-07-07 | — | — | US | disclosed |
| EP-0162383-A1 | Biologically active agent containing substituted isoxazolidines, isoxazolidines and their preparation | BAYER AG (DE) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224244-A1 | Adamantyl Benzamide Derivatives | HSD11B1, HSD17B11, HSD3B1 | GRIN2D 996/4885GRIN3B 1447/4885GRIN1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.